Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 15

384P - Disitamab vedotin (RC48) for previously treated HER2-expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single-arm, prospective phase II clinical trial

Date

14 Sep 2024

Session

Poster session 15

Topics

Clinical Research;  Targeted Therapy

Tumour Site

Breast Cancer

Presenters

Yun Wu

Citation

Annals of Oncology (2024) 35 (suppl_2): S357-S405. 10.1016/annonc/annonc1579

Authors

Y. Wu1, H. Mo1, X. Sun2, X. Peng1, F. Ma1

Author affiliations

  • 1 Department Of Medical Oncology,, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021 - Beijing/CN
  • 2 Department Of Medical Oncology, Huanxing Cancer Hospital, 100021 - Beijing/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 384P

Background

Disitamab vedotin (RC48) is an antibody-drug conjugate targeting HER2, demonstrating promising efficacy and safety in HER2-positive and HER2-low metastatic breast cancer (MBC). This study aimed to explore the efficacy and safety of RC48 in HER2-expressing pretreated MBC patients with abnormal activation of the PI3k/Akt/mTOR (PAM) pathway.

Methods

This single-arm phase II clinical trial recruited HER2-positive and HER2-low MBC patients who had progressed on at least one line of systemic chemotherapy with confirmed PAM pathway activation from September 2022 to December 2023. Patients received RC48 treatment (2 mg/kg IV infusion, once every 2 weeks). The primary endpoint was objective response rate (ORR), and secondary endpoints included disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and safety.

Results

As of Mar 15, 2024, a total of 62 patients with confirmed PAM pathway activation were enrolled, comprising 26 patients with HER2-positive MBC and 36 with HER2 low MBC. These patients had a median 2 prior lines of chemotherapy (range 1-9), with 79.0% receiving ≥2 lines of chemotherapy for metastatic disease. Prior treatments included taxane (98.4%), trastuzumab (96.2%) and CDK 4/6 inhibitors (61.5%). The median follow-up time was 13.2 months. The ORR for HER2-expressing MBC was 34.4% (21/61), with rates of 34.6% (9/26) in the HER2-positive patients and 34.3% (12/31) in the HER2 low-expression group. The median PFS with RC48 was 3.5 months (95%CI [confidence interval]: 2.4-4.6 months), with 4.5 months (95%CI: 2.9-6.1 months) in HER2-positive and 3.4 months (95%CI: 2.8-4.0 months) in HER2 low patients. In terms of safety, the most common grade 3 or higher treatment-related adverse events included neuropathy (11.3%), neutropenia (8.1%), aspartate aminotransferase elevation (3.2%), and leukopenia (3.2%), with no treatment-related deaths.

Conclusions

RC48 showed promising efficacy and manageable safety in HER2-positive and HER2-low pretreated MBC patients with abnormal PAM pathway activation. It may serve as a therapeutic option for HER2-expressing MBC patients with PAM pathway abnormalities.

Clinical trial identification

NCT05331326.

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

RemeGen Co., Ltd.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.